# A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

> **NCT02019485** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)
- **DRUG:** Tapentadol Prolonged-Release Formulation 2 (PR2)

## Key facts

- **NCT ID:** NCT02019485
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2013-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02019485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02019485, "A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02019485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*